1. Review of survival, safety, and clinical outcomes in HER2+ metastatic gastric cancer following the administration of trastuzumabPost-Trastuzumab Gastric Cancer
   Michelle D. Hackshaw et al, 2020, Cancer Treatment and Research Communications CrossRef
2. Current status and future perspectives in HER2 positive advanced gastric cancer
   G. Roviello et al, 2022, Clinical and Translational Oncology CrossRef
3. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives
   Juliette Palle et al, 2020, Drugs CrossRef
4. Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?
   Giandomenico Roviello et al, 2021, Gastric Cancer CrossRef
5. Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE)
   Shukui Qin et al, 2021, The Oncologist CrossRef
6. Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis
   Emil ter Veer et al, 2018, Acta Oncologica CrossRef
7. The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion
   Stefano Cascinu et al, 2022, Frontiers in Medicine CrossRef
8. Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203)
   Masanobu Takahashi et al, 2021, The Tohoku Journal of Experimental Medicine CrossRef
9. The addition of PD-1 inhibitor overcame trastuzumab resistance in patients with HER2 positive, PD-L1 negative metastatic gastric cancer: Case report and review of literature
   Zhenpeng Wen et al, 2024, Frontiers in Pharmacology CrossRef